Trillium reports Phase I data for TT-621 in mycosis fungoides

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported preliminary data from 10 patients with relapsed or refractory mycosis fungoides in the Phase I TTI-621-02 trial showing that intratumoral injection of TTI-621 (SIRPaFc, SIRPalphaFc) led to a "rapid" decline in Composite Assessment of Index Lesion Severity (CAILS) score in 9 patients. In three patients with Sézary syndrome, TTI-621 reduced circulating leukemic Sézary cells. TTI-621 was well tolerated with no dose-limiting toxicities (DLTs) reported. Data were presented at the American Society of Hematology meeting in Atlanta.

The open-label, dose-escalation, dose-expansion, U.S. trial is evaluating TTI-621 in about 54 patients with relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides and Sézary syndrome. The primary endpoint is DLTs. Intratumoral injection of 10 mg TTI-621 administered thrice weekly for two weeks was selected as the optimal induction dose...